Dear Editor,Esophageal cancer is the seventh most common malignant tumor in China and has the third highest fatality rate worldwide(Siegel et al.,2022).The most common type in China is esophageal squamous cell carcino...Dear Editor,Esophageal cancer is the seventh most common malignant tumor in China and has the third highest fatality rate worldwide(Siegel et al.,2022).The most common type in China is esophageal squamous cell carcinoma(ESCC),which has shown a promising response to immune checkpoint inhibitors(Doki et al.,2022;Sun et al.,2021).However,challenges remain in effectively using immunotherapy due to varying patient responses and difficulties in identifying suitable candidates.展开更多
基金supported by the Natural Science Foundation of China(Grant No.82373072)awarded to Z.N.the Key Project of Hebei Province Natural Science Precision Medicine Joint Fund(H2022201067)awarded to Z.N.the Natural Science Foundation of Hebei Province(Grant No.H2024206159)awarded to J.Z.
文摘Dear Editor,Esophageal cancer is the seventh most common malignant tumor in China and has the third highest fatality rate worldwide(Siegel et al.,2022).The most common type in China is esophageal squamous cell carcinoma(ESCC),which has shown a promising response to immune checkpoint inhibitors(Doki et al.,2022;Sun et al.,2021).However,challenges remain in effectively using immunotherapy due to varying patient responses and difficulties in identifying suitable candidates.
